The genome-editing system based on CRISPR-Cas is becoming a valuable tool for different applications in biomedical research, drug discovery and human gene therapy by gene repair and gene disruption, gene disruption of viral sequences, and programmable RNA targeting.
Medical technologies are already addressing multiple issues and keep on developing every day. As we get more knowledge on cellular biology of DNA and RNA, new targets emerge and new therapies find place. Kira Astakhova, Associate Professor, Nucleic Acid Center at the University of Southern Denmark discusses the latest advances in small molecule drugs, formulations, and drug combinations and the ways in which they go hand in hand with biomolecular drug development.
Patient education is an important factor in disease self-management, and when handled properly it has been found to have a significant, positive impact on improving patient outcomes.
The International Society of Cellular Therapy (ISCT) has decided to speak out regarding oncoming health budget cuts in the US due to fears of the consequences for science, clinical care and patients in the US and internationally. T
Dr.Livy A. Shivraj considers the ripples that futuristic techniques such as gene editing and predictive diagnostics could cause regarding today's global health care systems.
In his review Michael A. Popov, Director Researcher, Prime States Quantum Lab ltd , London bridges the results obtained by two communities focused on the CRISPR Cas9 tool and defines some future trends in this new area of genome editing fit withdirect applications in personalized medicine.
Pharma IQ brings you a round up of the latest developments within the Pharma and Biotech industries.
Here are some of the key M&A transactions and partnerships that took place in 2016.
As the term patient centricity continues to buzz in the pharma industry, data has emerged stating that US physicians have experienced an overwhelming amount of confusion from patients around direct to consumer (DTC) adverts.